AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital, dedicated to the development and ...

Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - ...

High-dose aflibercept, administered every 12 to 16 weeks for 96 weeks, improves visual acuity in several patient subgroups.

Collaboration and License Revenue: Collaboration and license revenue for the third quarter ended September 30, 2024 was $10.0 million, as compared to zero for the same period in 2023. The increase was ...

RVO biomarkers can be established using an AI that draws out from intravenous fluorescein angiography and baseline characteristics.

Sunir J. Garg, MD, reflects on the recent American Academy of Ophthalmology meeting in Chicago and shares key insights on managing diabetic macular edema (DME). Dr Garg highlights new data showing ...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

The ELEVATUM study is designed to investigate how faricimab impacts DME in Black Americans. By enrolling, you'll contribute ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

Macular edema, a complication of DR, is a slower leakage of fluid into the areas of the eye responsible for sharp vision, usually causing blurred vision. The annual exams can give advance warning of ...

Investigators presented numerous studies into new and developing therapies for diabetic macular edema and age-related macular degeneration that were aimed at reducing the treatment burden.